Virometix Announces Completion of Enrollment in Phase I Trial of V-212 — a Fully Synthetic, Serotype-Independent Vaccine Candidate Against Streptococcus Pneumoniae Virometix AG, a Swiss clinical-stage ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback